Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
Clin Dermatol
; 39(1): 52-55, 2021.
Article
in English
| MEDLINE | ID: covidwho-1300690
ABSTRACT
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, medical professionals have been overwhelmed by questions beyond the infection itself. In dermatology practice, clinicians have been facing difficulties about the management of chronic immune-mediated skin diseases. Issues arose, such as the grade of immunosuppression or immunomodulation, discontinuation or modification of treatment, and initiation of new treatments. In this comprehensive review, we present the current evidence about the course and management of chronic inflammatory dermatoses during the COVID-19 pandemic, focusing on psoriasis, atopic dermatitis, and hidradenitis suppurativa.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Psoriasis
/
Biological Products
/
Hidradenitis Suppurativa
/
Dermatitis, Atopic
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Clin Dermatol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS